(L to R) Co-first authors Alise Blake and Melissa Perrino, MD, St. Jude Department of Oncology and corresponding author Kim Nichols, MD, St. Jude Division of Cancer Predisposition director, Department of Oncology
Newswise — (MEMPHIS, Tenn. – June 20, 2024) Recent advances in genomic sequencing have revealed that 5–15% of children with cancer have an underlying genetic predisposition. Although genetic predispositions increase the risk for new tumors, it has been unclear when to begin surveillance for these tumors. St. Jude Children’s Research Hospital scientists showed that beginning surveillance soon after recognizing a patient’s predisposition often led to discovering one or more early-stage asymptomatic tumors. About half of these tumors could be completely removed by surgery alone, thus avoiding the need for toxic chemotherapies or radiation therapies. The findings inform clinical practice after genetic testing and were published today in JAMA Oncology.
“We’ve shown that following standardized surveillance protocols provides a very effective way to detect new tumors at their earliest and most treatable stages,” said corresponding author Kim Nichols, MD, St. Jude Division of Cancer Predisposition director, Department of Oncology. “Understanding whether children have an underlying genetic risk for cancer can greatly impact their clinical care, and proactive surveillance for new tumors is an important component of this care.”
Findings showed the benefit of early surveillance applied across multiple cancer types and predisposing conditions. The researchers examined 274 St. Jude pediatric patients with 35 different cancer-predisposing conditions over a median of three years. Surveillance revealed tumors in 27 patients, representing a broad array of solid and central nervous system neoplasms.
Early detection leads to better treatment
Conventional practice typically results in surveillance that begins months to years after detecting a genetic predisposition. Further, data on the effectiveness and outcomes of surveillance are sparse. Strikingly, most of the new cancers detected in the study were found with early surveillance right after the genetic predisposition was discovered. Nearly one out of every three tumors were found at the first surveillance intervention soon after diagnosis, and two out of three were found within two years of that initial surveillance visit. Surprisingly, this included a small subset of children already being treated for a different cancer.
“About 17% of the children had a new tumor identified while they were still undergoing treatment for a prior cancer,” Nichols said. “Often, providers wait until a child has finished treatment for their first cancer before they start screening for other potential malignancies. If you do that, it is possible you’re going to miss a new tumor. Providers should now recognize the importance of starting the recommended surveillance tests the moment they discover an underlying predisposition.”
Beginning surveillance right away also resulted in finding cancers in earlier stages. Without the early screening, many of the tumors would have remained unnoticed until much later because almost all were asymptomatic at the time of discovery. By finding these tumors at an early stage, oncologists could remove most of them by surgery alone. In addition, findings showed that most tumors (around 70%) were entirely removed without leaving even microscopic traces behind.
“We were able to remove these tumors without any evidence of disease left behind,” Nichols said. “These patients will have better outcomes and may need less or even no chemotherapy or radiation therapy.” Avoiding chemotherapy and radiation can prevent long-term treatment-related side effects, a poignant consideration when treating children.
Modern cancer surveillance methods worked, when available
To find potential cancers and guide treatment, clinicians used various surveillance methods. For example, a predisposition for a solid tumor may lead to annual full-body magnetic resonance imaging (MRI). Standard surveillance methods had minuscule false positive and false negative rates.
“Overall, across these different reports and reviews of the relevant images, there was an excellent performance of the different modalities,” Nichols said. “We had very few false positive or negative findings, meaning we did not need to pursue unnecessary interventions or miss any incipient tumors. Both factors are essential in optimizing the care for our patients with underlying predispositions”.
The study may enable more providers to order these effective, yet sometimes expensive, tests. It can be challenging for providers to get insurance companies to pay for early screening. Historically, this has created a difficult cycle where providers could not order the tests, which meant there was no strong evidence of their value, preventing their use. Patients at St. Jude are treated regardless of insurance coverage, thus enabling physicians to order the appropriate tests. The excellent performance of the standard screening methods is evidence that early testing can improve detection and outcomes. This may give insurance companies the evidence needed to cover the tests for children with a predisposition.
“I hope that providers will initiate recommended surveillance as soon as they learn that someone has an underlying predisposition,” Nichols said. “They shouldn’t hesitate to start looking as soon as they learn about the predisposition, and it’s imperative to follow through with that surveillance. Then, we can find these tumors early, while they are potentially easier to treat.”
Authors and funding
The study’s first authors are Alise Blake and Melissa Perrino, of St. Jude. The study’s other authors are Alise Blake, Melissa Perrino, Leslie Taylor, Rose McGee, Sara Lewis, Stacy Hines-Dowell, Arti Pandey, Paige Turner, Manish Kubal, Yin Su, Li Tang, Laura Howell, Lynn Harrison, Zachary Abramson, Ann Schechter and Noah Sabin, St. Jude; and Cara Morin, formerly of St. Jude.
The study was supported by grants from ALSAC, the fundraising and awareness organization of St. Jude.
St. Jude Media Relations Contacts
Chelsea Bryant
Desk: (901) 595-0564
Rae Lyn Hartley
Cell: (901) 686-2597
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer, sickle cell disease and other life-threatening disorders. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 60 years ago. St. Jude shares the breakthroughs it makes to help doctors and researchers at local hospitals and cancer centers around the world improve the quality of treatment and care for even more children. To learn more, visit stjude.org, read St. Jude Progress, a digital magazine, and follow St. Jude on social media at @stjuderesearch.
RSS